245 related articles for article (PubMed ID: 11130261)
1. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
Fishbane S; Kowalski EA
Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
[TBL] [Abstract][Full Text] [Related]
2. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.
Fishbane S; Wagner J
Am J Kidney Dis; 2001 May; 37(5):879-83. PubMed ID: 11325667
[TBL] [Abstract][Full Text] [Related]
3. Re: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
Hörl WH
Perit Dial Int; 2001; 21(5):527-8. PubMed ID: 11757843
[No Abstract] [Full Text] [Related]
4. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
5. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
6. Parenteral iron therapy options.
Silverstein SB; Rodgers GM
Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
[TBL] [Abstract][Full Text] [Related]
7. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
Prakash S; Walele A; Dimkovic N; Bargman J; Vas S; Oreopoulos D
Perit Dial Int; 2001; 21(3):290-5. PubMed ID: 11475345
[TBL] [Abstract][Full Text] [Related]
8. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
9. Intravenous iron.
Auerbach M; Rodgers GM
N Engl J Med; 2007 Jul; 357(1):93-4. PubMed ID: 17611217
[No Abstract] [Full Text] [Related]
10. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
11. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
12. Parenteral iron therapy: a single institution's experience over a 5-year period.
Laman CA; Silverstein SB; Rodgers GM
J Natl Compr Canc Netw; 2005 Nov; 3(6):791-5. PubMed ID: 16316614
[TBL] [Abstract][Full Text] [Related]
13. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
14. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
16. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
17. Is iron gluconate really safer than iron dextran?
Eichbaum Q; Foran S; Dzik S
Blood; 2003 May; 101(9):3756-7. PubMed ID: 12707229
[No Abstract] [Full Text] [Related]
18. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron in oncology.
Auerbach M; Ballard H
J Natl Compr Canc Netw; 2008 Jul; 6(6):585-92; quiz 592. PubMed ID: 18597712
[TBL] [Abstract][Full Text] [Related]
20. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
